IL152103A0 - Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations - Google Patents

Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Info

Publication number
IL152103A0
IL152103A0 IL15210301A IL15210301A IL152103A0 IL 152103 A0 IL152103 A0 IL 152103A0 IL 15210301 A IL15210301 A IL 15210301A IL 15210301 A IL15210301 A IL 15210301A IL 152103 A0 IL152103 A0 IL 152103A0
Authority
IL
Israel
Prior art keywords
hypertrophy
diseases associated
treatment
myocardial diseases
medicament combinations
Prior art date
Application number
IL15210301A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL152103A0 publication Critical patent/IL152103A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15210301A 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations IL152103A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (1)

Publication Number Publication Date
IL152103A0 true IL152103A0 (en) 2003-07-31

Family

ID=7638652

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15210301A IL152103A0 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
IL152103A IL152103A (en) 2000-04-13 2002-10-03 Use of bradycardiac substances for the preparation of medicaments for the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152103A IL152103A (en) 2000-04-13 2002-10-03 Use of bradycardiac substances for the preparation of medicaments for the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Country Status (33)

Country Link
US (2) US7208508B2 (enExample)
EP (2) EP1666042A3 (enExample)
JP (1) JP3905386B2 (enExample)
KR (1) KR20020089453A (enExample)
CN (1) CN1245963C (enExample)
AT (1) ATE330588T1 (enExample)
AU (2) AU2001270484B2 (enExample)
BG (1) BG65816B1 (enExample)
BR (1) BR0109996A (enExample)
CA (2) CA2575059A1 (enExample)
CY (1) CY1105081T1 (enExample)
CZ (1) CZ300549B6 (enExample)
DE (2) DE10018401A1 (enExample)
DK (1) DK1276476T3 (enExample)
EA (1) EA006977B1 (enExample)
EE (1) EE05099B1 (enExample)
ES (1) ES2266216T3 (enExample)
HR (1) HRP20020815A2 (enExample)
HU (1) HU228387B1 (enExample)
IL (2) IL152103A0 (enExample)
ME (1) MEP45908A (enExample)
MX (1) MXPA02009935A (enExample)
NO (1) NO330311B1 (enExample)
NZ (1) NZ521934A (enExample)
PL (1) PL215235B1 (enExample)
PT (1) PT1276476E (enExample)
RS (1) RS51478B (enExample)
SI (1) SI1276476T1 (enExample)
SK (1) SK286075B6 (enExample)
TR (1) TR200202326T2 (enExample)
UA (1) UA78679C2 (enExample)
WO (1) WO2001078699A2 (enExample)
ZA (1) ZA200208162B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP3045174A1 (en) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AR076913A1 (es) 2009-05-20 2011-07-20 Boehringer Ingelheim Vetmed Solucion farmaceutica bebible de telmisartan. metodo para preparar la solucion
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
EP2741735A1 (en) * 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts
ES2979279T3 (es) 2017-07-07 2024-09-25 Boehringer Ingelheim Vetmedica Gmbh Telmisartán para la profilaxis o el tratamiento de la hipertensión en gatos
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
KR960704915A (ko) * 1993-09-24 1996-10-09 제이코버스 코넬리스 레이서 신규한 데옥시 및 산소 치환된 당 함유 14- 아미노스테로이드 화합물 (novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds)
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
RU2243768C2 (ru) * 1998-07-10 2005-01-10 Новартис Аг Гипотензивная комбинация валсартана и блокатора кальциевых каналов
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
ES2266216T3 (es) 2007-03-01
PL215235B1 (pl) 2013-11-29
YU76902A (sh) 2006-05-25
AU2001270484B2 (en) 2007-01-25
SI1276476T1 (sl) 2006-10-31
EP1666042A2 (de) 2006-06-07
CN1422153A (zh) 2003-06-04
SK14582002A3 (sk) 2003-03-04
NO20024924D0 (no) 2002-10-11
DK1276476T3 (da) 2006-08-14
BR0109996A (pt) 2003-05-27
WO2001078699A3 (de) 2002-06-20
BG65816B1 (bg) 2010-01-29
NO20024924L (no) 2002-10-11
KR20020089453A (ko) 2002-11-29
EP1666042A3 (de) 2006-06-21
NZ521934A (en) 2007-05-31
PL357827A1 (en) 2004-07-26
EE200200590A (et) 2004-04-15
HUP0300917A3 (en) 2009-04-28
JP3905386B2 (ja) 2007-04-18
EA200201053A1 (ru) 2003-02-27
EA006977B1 (ru) 2006-06-30
EE05099B1 (et) 2008-12-15
CA2575059A1 (en) 2001-10-25
MXPA02009935A (es) 2003-02-12
HUP0300917A2 (hu) 2003-08-28
US20040014795A1 (en) 2004-01-22
JP2003535050A (ja) 2003-11-25
CZ20023752A3 (cs) 2003-03-12
MEP45908A (en) 2011-02-10
CY1105081T1 (el) 2009-11-04
IL152103A (en) 2008-07-08
RS51478B (sr) 2011-04-30
TR200202326T2 (tr) 2003-03-21
BG107103A (bg) 2003-04-30
CA2404120C (en) 2008-01-22
DE50110262D1 (de) 2006-08-03
HU228387B1 (en) 2013-03-28
CN1245963C (zh) 2006-03-22
DE10018401A1 (de) 2001-10-25
CA2404120A1 (en) 2001-10-25
UA78679C2 (en) 2007-04-25
PT1276476E (pt) 2006-09-29
ATE330588T1 (de) 2006-07-15
EP1276476B1 (de) 2006-06-21
HRP20020815A2 (en) 2004-12-31
WO2001078699A2 (de) 2001-10-25
US20070155679A1 (en) 2007-07-05
NO330311B1 (no) 2011-03-28
SK286075B6 (sk) 2008-03-05
CZ300549B6 (cs) 2009-06-10
EP1276476A2 (de) 2003-01-22
AU7048401A (en) 2001-10-30
ZA200208162B (en) 2003-10-17
US7208508B2 (en) 2007-04-24

Similar Documents

Publication Publication Date Title
AU7048401A (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
TW200505900A (en) Muscarinic agonists
BE2012C040I2 (enExample)
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
AP1893A (en) Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
WO2001001973A3 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2001021159A3 (en) Pharmaceutical composition of nateglinide and another antidiabetcagent
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
GB2352972A (en) Use of dexmedetomidine for icu sedation
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
PT1900362E (pt) Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas
EP1086099A4 (en) COMPOUNDS BASED ON SULFONIC ACID OR SULFONYLAMINO N- (HETEROARALKYL) -AZAHETEROCYCLYLAMIDE
Jefferson Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
MXPA03009099A (es) Agonistas de kappa-opiato para tratamiento de transtornos de vejiga.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2001009119A3 (en) Chemokine receptor antagonists
MY146601A (en) Chemokine receptor antagonists and methods of use therefor
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
WO2001000191A3 (en) Use of fosphenytion for the treatment of acute neuropathic pain
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders